12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Company News  |  Deals

Raptor, Universite Laval deal

Raptor received exclusive rights to technology from the university related to the use of cysteamine and related compounds to treat Parkinson's disease. According to research done at the university, cystamine (an oxidized form of cysteamine)...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >